CENTRAL LABORATORY FOR VIRAL ACTIVATION TRANSFUSION

最初的目标是确定病毒激活是否发生在 输血，如果白细胞去除或辐射可以防止 了 将收集临床和实验室数据。 CMV和 将在HIV-1感染的输血接受者中研究HIV-1。 的 该研究的初始部分将招募330名HIV-1感染者， 时间安排输血。 伽马射线的影响 和白细胞减少对CMV和HIV病毒血症的影响将使用 定量PCR和病毒培养。重复输血的影响，如果 也将进行评估。临床数据将于 输血患者 该研究将是一项多中心研究，330名HIV-1感染患者， CD 4计数低于250 cell/cc 3。 计划输血的患者将 在首次输血时进入研究， 随机分配至三组之一：接受未处理血液 成分、过滤的血液或辐照的血液。 患者将接受 以这种方式处理的血液成分持续一至两年。 将在输血前和输血时从个体中采集血液样本。 不同的时间间隔。这些样本将使用 聚合酶链反应技术和定量培养， 确定输血后是否发生CMV或HIV-1活化。 这些测试也将在病人不被检查的时候进行。 输血以确定基线值。 这些人将 还可以测试许多其他免疫学标记物， 指导委员会。 这些人还将接受一名 医生定期和监测的机会性 感染

The initial goal is to determine if viral activation occurs following blood transfusion and if leukocyte depletion or irradiation can prevent it. Both clinical and laboratory data will be collected. Both CMV and HIV-1 will be studied in HIV-1 infected transfusion recipients. The initial part of the study will enroll 330 HIV-1 infected patients at the time they are scheduled for transfusion. The effects of gamma irradiation and leukocyte reduction on CMV and HIV viremia will be examined using quantitative PCR and viral culture. The effect of repeated transfusion, if needed, will also be assessed. Clinical data will be collected on transfused patients. The study will be a multicenter study of 330 HIV-1 infected patients with CD4 counts below 250 cell/cc3. Patients scheduled for transfusion will be entered into the study at the time of their first transfusion and randomized to one of three arms: to receive unmanipulated blood components, filtered blood, or irradiated blood. Patients will receive blood components treated in this way for a period of one to two years. Blood samples will be taken from the individuals before transfusion and at varying intervals after transfusion. These samples will be studied using the polymerase chain reaction technology and quantitative culture to determine if activation of CMV or HIV-1 occurs following transfusion. These tests will also be done at intervals when the patient is not being transfused to determine the values at baseline. These individuals will also be tested for a number of other immunological markers as determined by the steering committee. The individuals will also be examined by a physician regularly and monitored for the presence of opportunistic infection.